Full Year 2022 Product Sales
The following table provides the top 20 Innovative Medicines Division product net sales to third parties in 2022 as well as the change compared with 2021:
| Brands |
Net Sales (USD m) |
% change (USD) |
% change (cc2) |
Brand classification by therapeutic area, other promoted brands or established brands |
|---|---|---|---|---|
| Cosentyx | 4,788 | 1 | 5 | Immunology |
| Entresto | 4,644 | 31 | 37 | Cardiovascular |
| Promacta/Revolade | 2,088 | 4 | 9 | Hematology |
| Gilenya | 2,013 | -28 | -24 | Neuroscience |
| Tasigna | 1,923 | -7 | -1 | Hematology |
| Lucentis | 1,874 | -13 | -4 | Other Promoted Brands |
| Tafinlar + Mekinist | 1,770 | 5 | 11 | Solid Tumors |
| Jakavi | 1,561 | -2 | 9 | Hematology |
| Zolgensma | 1,370 | 1 | 5 | Neuroscience |
| Xolair1 | 1,365 | -4 | 6 | Immunology |
| Sandostatin | 1,238 | -12 | -10 | Established Brands |
| Kisqali | 1,231 | 31 | 38 | Solid Tumors |
| Ilaris | 1,133 | 7 | 15 | Immunology |
| Kesimpta | 1,092 | 194 | 200 | Neuroscience |
| Galvus Group | 859 | -21 | -12 | Established Brands |
| Gleevec/Glivec | 745 | -27 | -22 | Established Brands |
| Exforge Group | 743 | -18 | -12 | Established Brands |
| Diovan Group | 652 | -16 | -9 | Established Brands |
| Kymriah | 536 | -9 | -2 | Hematology |
| Afinitor/Votubia | 512 | -45 | -41 | Established Brands |